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SUMMARY AND FUTURE PERSPECTIVES 
The aim of this dissertation is to discuss new targets, to apply multicomponent reaction chemistry 
on scaffolds significant for medicinal chemistry applications and to implement new modalities 
(PROTACs) in drug design and medicinal chemistry.
In chapters 1 and 2, the protein-protein interaction of PD-1 and PD-L1 is covered, as it represents 
one of the hottest targets in immune-oncology. The accumulation of structural data deriving 
from crystal structures has provided valuable insights on targeting the PPI. In the last five 
years, monoclonal antibodies blocking the interaction have reached the market, after showing 
impressive results in the clinic. Numerous clinical trials are on-going for monoclonal antibodies, 
either as monotherapy or as combination treatments. Nevertheless, there are still certain 
disadvantages in the use of monoclonal antibodies. The discovery of small molecules to block 
the interaction  has proven to be challenging. However, a few classes of small molecules and 
macrocycles have potential as inhibitors and these are discussed in detail, covering the recent 
patent literature. Moreover, the structural aspects of binding from antibodies, to small molecules 
and macrocycles are analyzed in an effort to provide a better understanding of hot-spots and 
structural requirements. The relatively new field of targeting immune checkpoint inhibitors 
provides a very promising approach in cancer research and the data shown here aim to offer a 
better understanding of the field. 
Figure 1. Examples of small molecules and macrocycles targeting the PD-1/PD-L1 PPI. 
As new, more challenging and complicated targets are appearing in medicinal chemistry and drug 
discovery, the need to develop faster synthetic routes to complex small molecules is increasing. The 
rapid screening of libraries of derivatives significantly accelerates the establishment of structure-
activity relationships (SAR). In this light, multicomponent reactions have a lot to offer, as they 
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provide access to complex scaffolds in a few synthetic steps. They show great tolerance to post-
modifications, making this type of chemistry attractive for intramolecular cyclizations towards 
drug-like molecules or the synthesis of macrocycles or numerous palladium-catalyzed reactions. 
In chapters 3, 4, 5, 6 and 7 applications of multicomponent reactions in diverse scaffolds are 
presented. 
In chapter 3, our aim is to design a synthetic route that would allow access to the natural products 
glutarimide alkaloids, as well as their derivatives. The described methods rely on protected 
aminoacids as starting materials and although this is sufficient for synthesizing the natural 
products, it is not suitable for derivatives. Thus, the current synthetic methods would not be useful 
for the further biological evaluation of libraries deriving from the glutarimide alkaloid scaffold. In 
this chapter, we design a synthetic route based on a four-component Ugi reaction, which already 
includes two point of variation for synthesizing derivatives. The peptidomimetic Ugi scaffold, after 
an ester hydrolysis, a cyclization and a deprotection under acidic conditions leads to optically 
pure natural products (Julocrotine, Crotonimide A, Crotonimide B and Crotonimide C), as well 
as ten derivatives of the natural alkaloids. The diversity for the derivatives is achieved by using 
commercially available starting materials. This type of methodology, is useful for studying the 
biological properties of glutarimide alkaloids and establishing structure-activity relationships. 
Moreover, it provides access to both S- and R-enantiomers of the alkaloids.
In  chapter 4, the beta-carbolinone scaffold is explored. This scaffold is present in natural products 
with diverse biological activities. The known methods usually require harsh conditions to access it. 
Here, we demonstrate that the main skeleton can be built by using an Ugi-four component reaction 
with an indole-carboxylic acid and propargyl-amine. In an one-pot fashion, without isolating 
the Ugi product, but by directly adding silver triflate in the reaction mixture, an intramolecular 
cyclization takes place and leads to the beta-carbolinone analogues. A library of 22 derivatives 
in high yields was synthesized. Docking studies of the synthesized compounds indicate that the 
derivatives could be useful as allosteric inhibitors of DAPK3 kinase, mimicking analogues of the 
natural product Bauerine C. 
In chapter 5, we show the potential of Ugi reactions in synthesizing complex indole-fused 
polyheterocycles. Indole-fused scaffolds, are not only observed in natural products, but are also 
useful in medicinal chemistry. A variety of synthetic methods is already described, however to the 
best of our knowledge, MCR reactions have not been applied previously in the synthesis of this 
scaffold. The initial Ugi product undergoes a palladium catalyzed-reaction towards the desired 
indolo[3,2-c]quinolinones. Remarkably, diversity can be achieved through all four-components 
of the Ugi reaction; the aniline, the aldehyde/ketone, the isocyanide and the indole-2-carboxylic 
acid. Regarding potential applications, docking studies indicate that these types of derivatives 
could be useful as kinase inhibitors. 
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In chapters 6 and 7, we shift our focus from natural product analogues to hetercocycles. 
Heterocycles are used extensively in medicinal chemistry and in most of the drugs on the market, 
at least one heterocyclic ring is present. They are used to increase biological affinity and tune 
the pharmacokinetic / pharmacodynamics properties of the molecules. Therefore, there is a 
constant need for developing better, faster and more efficient synthetic routes for heterocyclic 
compounds. In chapter 6, the scaffold of 2-(imidazo[1,5-α]pyridine-1-yl)-1,3,4-oxadiazoles is 
discussed. Although its biological importance is already established, the synthetic route to access 
it is lengthy and time-consuming. In particular, it requires six sequential steps and a number of 
purifications to reach the final product. We designed an MCR route, based on the Ugi-tetrazole 
reaction and simple, commercially available building blocks. With in situ deprotections and 
cyclizations, we were able to synthesize a library of derivatives with high diversity and reducing 
the necessary purifications to only one column purification in the final step to isolate the products. 
Therefore, this type of methodology would accelerate the further biological evaluation of this bis-
heterocyclic scaffold. In chapter 7,  we demonstrate that the combination of Ugi-tetrazole and 
Huisgen reactions successfully leads to poly-substituted 1,3,4-oxadiazoles. It should be noted that 
1,3,4-oxadiazoles are known bioisosteres for amides and esters and have various applications in 
medicinal chemistry and material science. With our methodology, numerous secondary amines, 
such as piperazine, morpholine and piperidine, that are known to be beneficial for solubility and 
tuning of PK/PD properties,  are incorporated  easily in the scaffold. A library of derivatives with 
high diversity was synthesized and it was shown that the method has excellent scalability and it 
tolerant to post-modifications. 
Figure 2. Scaffolds accessed via multicomponent reaction schemes. 
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In chapter 8, an MCR scaffold  was applied on aspartic proteases. A docking protocol was 
developed for tailor-made virtual libraries, using software freely accessible to academia. In a 
similar manner as the software AnchorQuery, which performs pharmacophore based-screening 
on MCR libraries, using amino-acid residues as anchors, we use here an anchor-based approach 
suitable for any fragment-type anchor that can be applied to broad scaffolds, as well as post-
modifications. The optimization of initial hits deriving from an Ugi-tetrazole reaction can be 
performed by creating virtual libraries for this particular scaffold, including commercially available 
starting materials. The biological screening, as well as the obtained co-crystal structures support 
the choice of the designed scaffold. We believe that the developed docking protocol will be 
applicable to numerous biological targets, without bias or limitation on the explored chemical 
space. 
In the last part of the thesis, chapters 9, 10 and 11, the focus is on a very exciting new modality in 
medicinal chemistry, the proteolysis-targeting chimeras (PROTACs). The term was first described in 
2001, but in the last few years the great potential of this approach has been clearly demonstrated. 
PROTACs are bifunctional molecules, targeting a protein of interest and an E3 ligase. In contrast 
to classical medicinal chemistry, where the aim is to inhibit a disease-related protein, PROTACs 
induce the degradation of the target by taking advantage of the normal proteasomal degradation 
process. In this relatively new field, in preclinical studies numerous targets have been successfully 
degraded and earlier this year the first clinical trial was announced. In chapter 9, in a review, the 
unique structural features of PROTACs, as well as their advantages over classical inhibition are 
discussed. Examples of the different types are shown and we focus in particular on structural 
data, their mechanism of action and kinetics. In chapter 10, the principles of PROTAC design were 
applied on the target cyclin-dependent kinases CDK4/6, which are involved in the regulation of the 
cell cycle and are a validated target for cancer. Since 2015, three dual kinase inhibitors have been 
approved by the FDA. However, achieving total selectivity has been elusive for small molecules. 
As shown in recent publication, selectivity could be tuned by PROTACs. Here, starting from 
abemaciclib, the last compound to gain FDA approval, and by applying structural modifications, 
abemaciclib-based PROTACs were designed and synthesized. The preliminary biological data are 
promising and the aim is to include in vivo studies for this target, which has not been performed 
yet by CDK4/6-PROTACs. 
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Figure 3. Structures of kinase inhibitors and examples of synthesized PROTACs. 
In Chapter 11, the rationale for designing and synthesizing PROTACs for the leucine-rich repeat 
kinase 2 (LRRK2) is presented. LRRK2 has emerged as a potential target for Parkinson’s disease and 
the first inhibitor entered clinical trials in 2018. Despite the plethora of highly potent and selective 
inhibitors, LRRK2 is a challenging target to inhibit. It is a very large, multi-domain protein and the 
crystal structure of those domains is not fully elucidated. For this project, two LRRK2 inhibitors were 
modified toward pomalidomide-PROTACs in order to evaluate the degradation potential on this 
target. Preliminary biological data indicate binding to the target, as well as cell penetration. Data 
regarding degradation are inconclusive. Therefore, a hypothesis for this observation is discussed. 
Overall, the aim of this thesis was to show that medicinal chemistry is a multi-disciplinary field 
that keeps evolving, as the focus is shifting from enzymes and proteins with well-defined pockets 
to protein – protein interactions and more challenging  targets. The choice of the target, affects 
also the type of necessary chemistry and drug design. Thus, medicinal chemists are constantly 
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